With a market cap of $18 billion, Moderna is at the forefront of innovative healthcare solutions, pioneering treatments for ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Standing out among the Street's worst performers today is Moderna, a biotechnology company whose shares slumped -6.9% to a ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating on October 28. Joseph Stringer has ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Moderna (MRNA) delivered earnings and revenue surprises of 101.59% and 47.73%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

2024 has generally been an exceptionally good year for equities. The S&P 500 index hit another all-time high on Wednesday, and it is up a healthy 24% year to date.